MedTrace Logo

Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)

NCT05770180 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2024-07-24

No results posted yet for this study

Summary

A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older after completing 2 or 3 doses of novel coronavirus inactivated vaccine (Vero cells)

Conditions

Interventions

BIOLOGICAL

Recombinant COVID-19 variant vaccine (Sf9 cell)

WSK-V102

BIOLOGICAL

Recombinant COVID-19 vaccine (CHO cell)

control 1

BIOLOGICAL

Recombinant COVID-19 vaccine (Sf9 cell)

control 2

Sponsors & Collaborators

  • WestVac Biopharma Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-03-30
Primary Completion
2023-07-30
Completion
2024-04-09

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05770180 on ClinicalTrials.gov